DSM Biologics, a business unit of DSM Pharmaceutical products, has reached an agreement for the acquisition of the assets and associated business of the RHOBUST® technology from Upfront Chromatography A/S (Denmark) for pharmaceutical and other applications. As a result of the acquisition, DSM Biologics will gain all rights for the commercialization of the RHOBUST® technology in various fields, including the pharma industry. The RHOBUST® technology will lead to further innovation in the downstream processing for the manufacturing of recombinant proteins and antibodies.
The RHOBUST® technology has proven its ability to perform with high titer and high density cell culture processes. Compared to a conventional harvest approach, the number of unit operations is reduced. The cells are separated in one step while capturing the protein/antibody of interest. In the expanded bed adsorption chromatography (EBA) the cell suspension passes through the column and the product is adsorbed either on Protein A or on mixed mode ligand beads. This leads to less handling and shorter process times.
The RHOBUST® technology combined with DSM’s proprietary XD® technology will provide an integral package combining high titer, high yield processing with efficient downstream processing leading to lower manufacturing costs.”
